Niagen Bioscience heads into the week with one of the most striking options sentiment reversals in the past year — call buyers have overwhelmed the market with an aggression that places the current read near the year's most bullish extreme.
Options positioning has swung sharply in the bulls' favour. The put/call ratio collapsed to 0.24 by Tuesday, more than 2.4 standard deviations below its 20-day mean of 0.54. That is the second-lowest reading of the past 52 weeks, with only the 0.157 floor providing a lower baseline. What makes the move more striking is the speed: through most of April, the PCR sat in a tight 0.57–0.67 band, then broke hard lower starting May 1. Options traders flipped from measured to emphatic in the space of three sessions.
Short interest and borrow conditions tell a different story — one that is notably relaxed given the enthusiasm showing up in options. Short interest came in at roughly 6.9% of the free float by ORTEX's daily estimate, edging down about 0.2% on the day and essentially flat on the week. The borrow cost is low at 0.51% APR, off about 4% on the week. Availability is wide — about 623% of current short interest — meaning there is ample stock to borrow for anyone who wants to build a fresh short position. Nothing in the lending market signals either squeeze pressure or a meaningful conviction build from the bear side.
Canaccord Genuity is the only active voice on the Street. The firm has maintained a Buy rating throughout but has been methodically trimming its price target: from $16 in mid-2025 down to $10 as of May 5, when analyst Susan Anderson lowered her target again from $13. At $4.82, the stock trades at less than half the revised $10 target — a gap that reflects either genuine upside potential or a target still catching down to reality after the stock's volatile run. The PE multiple is running around 18x, with a price-to-book near 5.4x — not cheap for a personal care products company, but the earnings surprise factor score ranks in the 92nd percentile, signalling the company has consistently beaten lowered expectations. The short score sits at 55.9 — mid-range, not flashing alarm.
The most significant institutional detail in the ownership picture is structural: Hoi Shuen Chau holds 24% of shares, effectively anchoring the float. Vanguard added roughly 655,000 shares in the quarter to March 31, making it the most active buyer among the passive giants. Dimensional Fund Advisors added about 195,000 shares over the same period. Neither move is dramatic relative to float, but both add passive ballast to a stock that has already more than doubled year-to-date.
The stock itself is up around 10% on the one-month horizon but gave back about 2% on Tuesday, closing at $4.82. The Canaccord target cut arrived the same day — the most recent catalyst in the window. Closest correlated peers in the personal care space had a firmer week: EL and SKIN both gained more than 7% on the week, while UPXI added 5.3%. NAGE barely moved on the week at -0.4%, a notable divergence given the bullish options signal.
The setup worth watching is whether the call-heavy options posture reflects a specific catalyst the market is anticipating — the earnings history shows an event dated May 6 — or whether the PCR compression resolves quietly as near-dated options expire.
See the live data behind this article on ORTEX.
Open NAGE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
